Established in 1997, Prana Biotechnology is a world leader in addressing the role of biological metals in human disease. Abundant scientific evidence suggests that many age-related conditions result from pathological interactions between selected metals and target proteins. The company has developed a proprietary library of chemical compounds that target these interactions, preventing protein aggregation and corruption. The mission of the company is to develop disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's diseases. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration.

Latest News  19 June 2013 Prana Presents New Benchmark Test to Assess HD Patients in Clinical Trials      Learn more      View Full Poster  3 May 2013 Prana Announces Share Purchase Plan Closed      Learn more 4 April 2013 Prana Announces  $5.8 million R&D Refund      Learn more 3 April 2013 Prana Provides Clinical Trials Safety and Progress Update.      Learn more 27 March 2013 Prana Announces Successful A$7 million Capital Raising       Learn more 8 March 2013 Prana Details PBT2 Data on Reduced Tau Cognitive Impairment       Learn more 6 March 2013 Prana's PBT434 Inhibits Parkinson's Protein & Brain Cell Death       Learn more 4 March 2013 Prana Announces That PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation       Learn more 26 February 2013 Prana to Provide a Company Overview and Update at the Cowen & Company 33rd Annual Health Care Conference in Boston on 4th March 2013.         Learn more         Access the Webcast      30 January 2013 Prana Announces NYAS Symposium eBriefing Available Online        Learn more 21 December 2012 Burrill Institutional Research Report       Learn more 19 December 2012 Prana Completes Recruitment in Huntington Trial        Learn more   13 December 2012 Journal of Huntington's Disease Publishes Benefits of PBT2       Learn more  6 December 2012 New York Academy of Sciences Symposium Discusses PBT2      Learn more 27 November 2012 Prana Completes Recruitment in Alzheimer's Trial      Learn more   20 November 2012 Prana to Present at New York Academy of Sciences Symposium      Learn more For details of the NYAS Symposium and webinar registration       Click here   14 November 2012 Prana Provides Huntington Disease Trial Update       Learn more 1 October 2012 Prana Announces A$6 Million Capital Raising       Learn more     PBT2 Therapeutic Strategy Statement Subscribe / E-mail alerts